Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | IL1RN | P18510 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163139 | 1.00 | BACE1 (0.42) | BACE1BACE2ERAP2CTSDCTSB | |
| SCHEMBL3863461 | 0.91 | BACE1 (0.46) | BACE1BACE2CTSDCTSB | |
| SCHEMBL3863451 | 0.91 | BACE1 (0.46) | BACE1BACE2CTSDCTSB | |
| SCHEMBL7838077 | 0.91 | BACE1 (0.46) | BACE1BACE2CTSDCTSB | |
| SCHEMBL7838083 | 0.91 | BACE1 (0.46) | BACE1BACE2CTSDCTSB | |
| SCHEMBL30658572 | 0.90 | ERAP2 (0.40) | BACE1ERAP2IL1RNERAP1 | |
| SCHEMBL29532207 | 0.90 | MME (0.41) | — | |
| SCHEMBL31471617 | 0.89 | BACE1 (0.45) | BACE1BACE2CTSD | |
| SCHEMBL21148859 | 0.89 | ERAP2 (0.40) | BACE1BACE2ERAP2IL1RNERAP1 | |
| SCHEMBL20397445 | 0.89 | FNTA (0.37) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506628-B1 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA TAU IND FARMACEUTI (IT) | 1996-09-18 | — | — | EP | claimed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | claimed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | claimed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0506628-B1 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA TAU IND FARMACEUTI (IT) | 1996-09-18 | — | — | EP | disclosed |
| US-5298621-A | Peptides endcapped with purine derivative | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5298621-A | Peptides endcapped with purine derivative | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5272151-A | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-21 | — | — | US | disclosed |
| US-5272151-A | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-21 | — | — | US | disclosed |
| EP-0506628-A3 | AMINOACYL AND OLIGOPEPTIDYL DERIVATIVES OF ALLOPURINOL EXHIBITING IMMUNOSTIMULATORY ACTIVITY, AND PHARMACEUTICAL FORMULATIONS CONTAINING THESE SUBSTANCES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-10-21 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | BACE1 3533/4885BACE2 3392/4885ERAP2 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.